HHS Peptide Enforcement Policy Explained | telos rx
Quiet wooden reading room with a desk and chair beside a sunlit arched window
← Back to blog
BPC-157

HHS Peptide Enforcement Policy Explained

By telos rx Editorial Team

The HHS peptide enforcement policy, published 30 October 2026, says HHS will not act against licensed compounders using six peptides under strict conditions. It is not FDA approval and can change. See how telos rx offers BPC-157.

Written by the telos rx Editorial Team. Last reviewed: 16 November 2026.

If you have read that peptides like BPC-157 are suddenly available from pharmacies, this is the policy behind the headlines. The details matter, because the policy is narrow, conditional and temporary.

This explainer covers what the policy says, which peptides and routes it covers, what it does not do, and what it means if you are considering a peptide prescription.

What the HHS peptide enforcement policy is

On 30 October 2026, the Department of Health and Human Services published a notice in the Federal Register, document 2026-22192 (91 FR 68526). It announced an interim enforcement discretion policy for compounding with certain peptide bulk drug substances.

Enforcement discretion means HHS has said it does not intend to take enforcement action in certain situations. It does not change the underlying law. The notice describes the policy as a draft that is not binding on HHS or the public.

The policy applies to state-licensed pharmacies, federal facilities and licensed physicians compounding under federal compounding rules. It stays in place until each peptide is addressed in a final rule on the list of bulk substances that pharmacies may use.

Which six peptides are covered

Appendix A of the policy lists six peptides. Appendix B limits each one to specific routes of administration.

Peptide Routes covered by the policy Notes
BPC-157 Subcutaneous, intramuscular, oral, topical Acetate form
TB-500 Subcutaneous or intramuscular Acetate form
MOTS-c Subcutaneous or intramuscular Acetate form
Epitalon Subcutaneous or intramuscular Intermittent courses only
Semax Intranasal only Free base form
KPV Topical and oral only Acetate form

Peptides not on the list, such as Selank and DSIP, are not covered.

The conditions compounders must meet

HHS says it will hold back only when all of the conditions are met. In plain terms, they are:

  1. The peptide is one of the six on the list.
  2. It matches the identity and route limits in Appendix B.
  3. The raw ingredient comes from an FDA-registered facility with a valid certificate of analysis showing identity, purity, potency and contaminant testing.
  4. The original manufacturer is FDA-registered and meets good manufacturing practice requirements.
  5. Serious adverse events and product quality problems are reported to FDA MedWatch and to the relevant states.
  6. The label states: "This is a compounded drug product. Not for resale."
  7. Each product contains a single active ingredient from the list.
  8. Oral forms come with documentation that the formulation is adequately absorbed in humans.
  9. The only device packaged with the product is an FDA 510(k)-cleared syringe.
  10. The product meets all other legal requirements, including a valid patient-specific prescription.

Why single ingredients matter

The single-ingredient rule rules out blends. Products marketed as peptide "stacks" in one vial fall outside the policy.

HHS explained that single-ingredient products make it easier to link a side effect or outcome to one substance. That helps safety monitoring.

Interested in BPC-157 through a licensed provider?

telos rx offers compounded BPC-157 as a single-ingredient product after an online clinical review. It is not FDA-approved, and any prescription is subject to medical approval by a licensed provider.

Learn about BPC-157

What the policy does not do

  • It is not FDA approval. Compounded peptides remain not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold, as its human drug compounding page explains.
  • It is not a final listing. The peptides have not been added to the official bulk substances list.
  • It is not permanent. HHS says it may revisit the policy if a safety signal or quality problem appears.
  • It does not cover research-use-only products, supplements or peptides bought without a prescription.
  • It does not prove anything works. It is a decision about enforcement, not about effectiveness.

Why HHS issued the policy

HHS said the policy aims to discourage the widespread use of research-use-only peptides from foreign suppliers, which it described as a safety risk. Allowing limited compounding under safeguards gives patients a more controlled alternative.

The background is mixed. FDA drug reviewers had recommended against listing these peptides. The Pharmacy Compounding Advisory Committee voted in favor. HHS pointed to the committee vote, newly documented use and new quality testing data.

The evidence is still thin

Enforcement discretion says nothing about how well these peptides work. For most of them, human research is small, uncontrolled or absent.

Take BPC-157. A 2026 systematic review of human BPC-157 studies found only three studies with 30 people in total, all of poor quality. Most BPC-157 research is in animals. Animal results often do not carry over to people.

Similar gaps exist for the other five peptides. Read our recovery peptides overview for a closer look at the research.

What it means if you are considering a peptide

  1. You need a prescription. A licensed clinician must review your health history first.
  2. Ask where it is made. The pharmacy should be state-licensed and able to explain its sourcing.
  3. Expect single-ingredient products. A blended vial is a red flag under this policy.
  4. Check the route. For example, Semax is covered only as a nasal spray, and KPV only in topical and oral forms.
  5. Know how to report side effects. The label should explain how.
  6. Athletes, check the rules. Several of these peptides are prohibited in tested sport.

What could change next

The public comment period on the docket closed on 14 November 2026. FDA may later propose adding some or all of the six peptides to the bulk substances list through rulemaking. Any peptide could also be left off.

HHS can revise or withdraw the interim policy at any time. Rules can change, so check the Federal Register notice and current HHS guidance for the latest version. This article reflects the policy as checked on 16 November 2026.

How telos rx works within the policy

telos rx is an online-first, asynchronous telehealth service. You complete an intake online, a licensed provider reviews it, and you message your care team rather than booking video calls.

telos rx offers compounded BPC-157 as a single-ingredient product, listed as low as $116 per month on the BPC-157 page as of 16 November 2026. BPC-157 and TB-500 are available only as two separate single-ingredient vials, never one blend, on the BPC-157 and TB-500 page. The provider sets any dose and form. See our peptide therapy cost guide and eligibility guide for more.

Start a private peptide evaluation

Answer health questions online, on your schedule. A licensed provider reviews them, and any prescription is subject to medical approval by a licensed provider.

Check my eligibility

Frequently Asked Questions

What is the HHS peptide enforcement policy?

It is an interim policy published in the Federal Register on 30 October 2026. HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding six listed peptides, as long as strict conditions are met. It is not FDA approval, and HHS can revise it.

Which peptides does the HHS policy cover?

Six peptides: BPC-157, TB-500, MOTS-c, epitalon, Semax and KPV. Each is limited to certain routes. BPC-157 covers subcutaneous, intramuscular, oral and topical forms. TB-500 and MOTS-c cover injection only. Epitalon covers injection in intermittent courses. Semax covers nasal use only, and KPV covers topical and oral forms only.

Does the HHS policy mean BPC-157 has FDA approval?

No. Compounded BPC-157 is not FDA-approved. The policy only describes when HHS does not intend to take enforcement action against compounders. It is not a final rule, it does not add BPC-157 to the official bulk substances list, and it says nothing about whether the peptide works.

Are peptide blends covered by the HHS policy?

No. One of the conditions is that each compounded product contains a single active ingredient from the list. Blended vials, often sold as peptide stacks, fall outside the policy. If a provider prescribes two peptides, they should come as separate single-ingredient products.

Are Selank and DSIP covered?

No. Only the six peptides in Appendix A are covered: BPC-157, TB-500, MOTS-c, epitalon, Semax and KPV. Selank and DSIP are not on that list, so the interim policy does not apply to them. Rules can change, so check current HHS guidance before relying on any summary.

Can the HHS peptide policy change?

Yes. HHS says it may revisit the policy in whole or in part if a safety signal or product quality issue arises. FDA may also address each peptide in a final rule, which could include or exclude it. Check the Federal Register notice and HHS guidance for the current version.

telos rx is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.

Ready to see if it fits? Start your private evaluation with telos rx.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX